Educational Symposium
What's New with SGLT2 Inhibitors in 2023
November 02, 2023 | 12:45 PM - 01:45 PM
Location: Grand Ballroom Salon A, Level 5, Philadelphia Marriott Downtown
Session Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated beneficial effects in clinical trials on kidney-related, cardiovascular, and heart failure outcomes in CKD patients with and without type 2 diabetes and in patients with heart failure. The application of these therapeutics only continues to expand. Importantly, there have been other recent novel therapies in the CKD therapeutic arena. There is now an opportunity to move toward "goal-directed medical therapy" in CKD. This symposium reviews what's new in 2023 with SGLT2 inhibitors and how to approach use of these medications in the context of established and newer therapeutics. Additionally, this symposium reviews the practice tips and potential pitfalls in prescribing these medications in practice.
Support is provided by an educational grant from AstraZeneca.
Learning Objective(s)
- Discuss the newest data on SGLT2 inhibitors, including patients that are good candidates
- Describe effective approaches and possible challenges in the real-world prescribing of these medications
- Develop an approach to prescribing these medications in combination with other CKD medications
Learning Pathway(s)
- CKD Non-Dialysis
- Diabetic Kidney Disease
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Moving Toward Goal-Directed Medical Therapy in CKD: Updates in SGLT2 Inhibitors and Use with Other Novel Therapies
12:55 PM - 01:15 PM
- Pearls and Pitfalls of Implementing SGLT2 Inhibitors to the Bedside
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM